 NEW YORK, Sept. 28, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 6-7: B T Cell-Mediated Autoimmune Disease Drug Development Summit. 